COCRYSTAL PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
COCRYSTAL PHARMA, INC. (COCP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.29% for the 1-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-13
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.83%.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 0.00%.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 1.64%, a 57.69% increase year-over-year.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.04%, a 9.47% increase year-over-year.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.96%, a 37.02% increase from fiscal 2022.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.89%, a 217.58% increase from fiscal 2021.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.91%, a 106.82% increase from fiscal 2020.
- COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.44%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.29% 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 3.83% 10-Q · filed 2026-05-15 | ||||
| 2026-01-31 | 3.83% 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-15 | ||||
| 2023-12-31 | 3.96% 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 2.33% 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | 1.64% 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | 1.64% 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 2.89% 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | 1.64% 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | 1.04% 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | 1.04% 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 0.91% 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | 0.91% 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | 1.08% 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | 0.95% 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | 0.44% 10-K · filed 2022-03-23 | ||||
| 2020-09-30 | 0.43% 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | 0.43% 10-Q · filed 2020-08-06 | ||||
| 2019-09-30 | 2.99% 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | 2.90% 10-Q · filed 2020-08-06 | ||||
| 2018-12-31 | 2.99% 10-K · filed 2020-03-27 | ||||
| 2012-09-30 | 0.83% 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | 0.83% 10-Q/A · filed 2012-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |